Table 1.
Demographic and clinical characteristics of patients groups with confirmed COVID‐19 patients
| Confirmed COVID‐19 group, n = 251 | |
|---|---|
| Age, years, mean ± SD | 8.92 ± 6.01 |
| Age distribution, n (%) | |
| <1 year | 34 (13.5) |
| 1–<6 years | 61 (24.3) |
| 6–<10 years | 38 (15.1) |
| 10–<15 years | 61 (24.3) |
| ≥15 years | 57 (22.5) |
| Gender, male, n (%) | 139 (55.5) |
| Underlying diseases, n (%) | |
| Previously healthy | 183 (72.9) |
| Chronic pulmonary disease | 11 (4.4) |
| Neurologic disease | 9 (3.6) |
| Bone marrow/solid organ transplantation | 8 (3.2) |
| Metabolic disease | 7 (2.8) |
| Hematologic–oncologic malignancy | 6 (2.4) |
| Rheumatologic disease | 6 (2.4) |
| Endocrine disorder | 5 (2) |
| Primary immune deficiency | 5 (2) |
| Nephrological disease | 3 (1.2) |
| Cardiovascular disease | 2 (1.8) |
| Others | 6 (2.4) |
| Signs and symptoms, n (%) | |
| Fever | 143 (57) |
| Cough | 60 (23.9) |
| Myalgia | 37 (14.7) |
| Dyspnea | 20 (8) |
| Sore throat | 20 (8) |
| Abdominal pain | 15 (6) |
| Headache | 11 (4.4) |
| Runny nose | 11 (4.4) |
| Diarrhea | 9 (7.4) |
| Fatigue | 9 (3.6) |
| Vomiting | 7 (2.8) |
| Anosmia | 5 (2) |
| Othersa | 7 (2.8) |
| Clinical classifications of illness severity, n (%) | |
| Asymptomatic | 48 (19.1) |
| Mild | 183 (72.9) |
| Modarate | 16 (6.4) |
| Severe | 1 (0.4) |
| Critical | 3 (1.2) |
| Hospitalization, n (%) | 55 (21.9) |
| Total length of hospital stay, days, mean ± SD | 7.59 ± 8.36 |
| Treatment, n (%) | |
| Hydroxychloroquine | 15 (6) |
| Antibiotic treatmentb | 19 (7.6) |
| Favipiravir | 8 (3.2) |
| Corticosteroid | 3 (1.2) |
| Salbutamol | 3 (1.2) |
| Oxygen support, n (%) | 6 (2.4) |
| PICU admission, n (%) | 3 (1.2) |
| Mechanical ventilator, n (%) | 3 (1.2) |
| Mortality, n (%) | 0 (0) |
Abbreviations: COVID‐19, coronavirus disease 2019; PICU: pediatric intensive care unit.
a
Other symptoms: Febrile convulsion in three patients, conjunctivitis in one patient, rash in one patient, chest pain in one patient, epistaxis in one patient, nausea in one patient.
b
Antibiotic treatment: Azithromycin + ceftriaxone used in three patients, ceftriaxone used in six pateints, meropenem used in six patients, piperacillin–tazobactam used in three patients, ciprofloxacin used in one patient.